ReviewCurrent psychiatry reports2022
The Emerging Field of Psychedelic Psychotherapy.
Review in Current psychiatry reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 48 citations in OpenAlex.
- Moving beyond 5-HTPsychopharmacology · 2026Article
- Psilocybin modulates social behaviour in male and female mice in a time-dependent manner.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Psilocybin Treatment as an Adjunct to Cognitive Behavioral Therapy for Eating Disorders: Therapeutic Rationale & Considerations for Protocol Development.Behavioral sciences (Basel, Switzerland) · 2026Review
- Synergies in psychedelic-assisted therapy: a qualitative interview study of psychotherapeutic processes.Frontiers in psychiatry · 2026Article
- Attitudes toward psychedelic therapy among medical and nursing students: A cross-sectional survey study.PloS one · 2026Article
- Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.Current topics in behavioral neurosciences · 2026Review
- Aquahenosis: a non-pharmacological altered state of consciousness induced by floatation-REST in individuals with anxiety and depression.Neuroscience of consciousness · 2026Article
- Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study.Acta neuropsychiatrica · 2025Article
- Review
- Is there a place for psychedelics in sports practice?Acta neuropsychiatrica · 2025Review
- Naturalistic psychedelic experiences and gender-based self-acceptance in transgender and gender-expansive people.International journal of transgender health · 2025Article
- Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials.JAMA psychiatry · 2025Review
- Therapeutic Potential of MDMA- and Psychedelic-Assisted Psychotherapy for Adolescent Depression and Trauma.Current psychiatry reports · 2025Review
- The Future of the Psychiatrist.Psychiatric research and clinical practice · 2025Article
- Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes.Frontiers in psychiatry · 2025Article
- Music as a collaborating actor: new insights into the nature and role of music in psychedelic-assisted psychotherapy.Frontiers in psychiatry · 2025Article
- Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics.Frontiers in psychiatry · 2025Article
- Article
- Article
- Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewFew treatments are available for patients with mood disorders or post-traumatic stress disorder (PTSD) who have already failed multiple interventions. After several decades when research into psychedelics was effectively halted by federal legislation, the past several years have shown the re-emergence of thoughtful investigations studying the utility of compounds such as 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin. RECENT
findingsSeveral studies have coupled the safe administration of psychedelic compounds in a controlled environment after several hours of preparation of study participants and followed by multiple sessions to integrate the psychedelic experience. The improvement participants experience appear related to the often profound perspective changes experienced and seem unlike the improvements seen in the currently available care paradigms. Studies cited include treatment resistant depression, end of life despair, and PTSD. Psychedelic psychotherapy, a unique remarriage of biological therapy and psychotherapy, has the potential to transform mental health care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.